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ABSTRACT
Atherosclerosis is a major cause of cardiovascular morbidity and can lead to
complications such as stroke and myocardial infarction. Ginseng, a natural health
supplement, has been shown to have anti-atherogenic properties, including
attenuating inflammation, oxidation and hyperlipidemia. I examined the effects of
North American ginseng on inflammation-associated VCAM-1 and ICAM-1
expression in cultured porcine endothelial cells and monocyte adhesion to the
activated endothelium in hypercholesterolemic and hyperhomocysteinemic rats. No
definitive downregulation of inflammatory VCAM-1 and ICAM-1 expression was
observed in vitro and only an aqueous ginseng extract was effective in reducing
homocysteine-induced monocyte adhesion to the aortic endothelium. I also examined
the effects of North American ginseng on lesion progression in a rabbit model of
atherosclerosis, but found no significant effects on serum total cholesterol, lesion area
or lesion composition. Further studies are required to determine if trends seen here
would yield a more robust result in a larger study.
Key wo rd s: Panax quinquefolius; North A merican ginseng; atherosclerosis;
inflammation; adhesion molecules; VCAM-1; ICAM-1; cholesterol; homocysteine;
rat; rabbit; endothelium; aorta
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CHAPTER 1

INTRODUCTION

1.1 ARTERIAL ANATOMY
1.1.1 Layered Structure
Atherosclerosis is a disease of the medium to large sized arteries, and as such,
these arteries, specifically the aorta, will remain the focus of this study. The aorta,
like other medium to large sized arteries has a common three-layered structure. The
innermost layer is known as the tunica intima, followed by the tunica media and the
tunica adventitia, moving outwards.1 The media of large, elastic arteries like the aorta
contain elastic laminae throughout the media between layers of smooth muscle cells
as well as two elastic layers separating the media from the intima on one side and the
adventitia on the other, known as the internal and external elastic laminae,
respectively. The layers are easily differentiated based on their cellular composition,
each serving a specific purpose in normal arterial function.
1.1.2 Cell Types
The innermost layer, the tunica intima, is composed mainly of collagen and
proteoglycans as well as other extracellular matrix components. Lining the inside of
the arteries is a monolayer of endothelial cells, serving as an anti-thrombogenic
barrier by mediating platelet adhesion and coagulation. In addition, it serves to
regulate vascular tone - and therefore blood pressure - and immune processes, most
importantly for this study, inflammation.3,4 The next layer is the tunica media,
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separated from the intima by the internal elastic lamina. The media is composed
mainly of smooth muscle cells as well as elastic tissue, and in large, muscular arteries,
is responsible for alterations in vascular tone. This study will focus on the aorta,
which is an elastic, large artery. The outermost layer, the tunica adventitia is
separated from the media by the external elastic lamina. The adventitia is primarily
made up of connective tissue, specifically collagen, and serves to anchor blood
vessels in place and to carry both a blood supply and innervation for the vessel wall.
In atherosclerosis, the endothelial cells from the intima and the smooth muscle cells
of the media can become ‘activated’ leading to an altered phenotype, causing
increased permeability, adhesion molecule expression and leukocyte recruitment by
the endothelium and increased proliferation and secretion of extracellular matrix
proteins by smooth muscle cells. 2 ’5

1.2 ATHEROSCLEROSIS
Cardiovascular disease is a leading cause of death worldwide, becoming more
s
prevalent in developing countries where increases in smoking and consumption of a
high-fat “Western” diet are common.2,6’7 Side effects of available treatments create
an important need to research alternative treatments for cardiovascular disease and
associated complications. Atherosclerosis is characterized by a narrowing of the
arterial lumen following lipid deposition in the vessel wall, fibrous plaque formation,
and potential rupture of the fibrous cap.8' 11 Atherosclerosis is a systemic disease with
clinical manifestations seen throughout the body, such as myocardial infarct - heart
attack - due to blockage of the coronary arteries, or embolic stroke caused by a
blockage of the blood supply to the brain by an aberrant blood clot or piece of
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atherogenic plaque.5' 1215 It was originally believed that the major determinant in
severity of atherosclerosis and likelihood of a cardiac event was stenosis of the vessel
resulting from smooth muscle cell proliferation in the plaque, but it has since been
determined that the vulnerability of a plaque to rupture or ‘activate’ is more critical.16
Plaque rupture exposes contents of the necrotic core such as tissue factor,
extracellular matrix components and lipids to the blood, leading to formation of a
thrombus capable of obstructing blood flow, and therefore causing ischemic death of
tissues supplied by these vessels. ’

As cardiovascular disease is the number one

cause of death worldwide, further research is required to better predict atherosclerosis
and develop treatment strategies to prevent or attenuate the atherosclerotic disease
process to limit the burden of such a condition.
1.2.1 Hypotheses of Atherosclerosis
Atherosclerosis was previously thought to be a passive, degenerative condition in
aging people, but is now well accepted to be an inflammatory condition, caused by
active cellular processes. Previous hypotheses include the response-to-injury
hypothesis, ’ the response-to-retention hypothesis, ' and the oxidative
modification hypothesis,38'52 all of which contributed various components to the now
well accepted inflammatory hypothesis.

r^

1.2.1.1 The response-to-injury hypothesis
The response-to-injury hypothesis was the first to suggest that atherosclerosis was
caused by active cellular processes as opposed to lesion formation caused by the
passive accumulation of lipid and accompanying pro-thrombogenic factors.

The

overlying principle of the response-to-injury hypothesis is that atherosclerosis is a
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result of vascular injury and that the associated pathologies are a result of a natural
attempt to heal the vascular injury. A major point of contention with the response-toinjury hypothesis was the suggestion that endothelial denudation was required for the
formation of atherosclerotic lesions, which with further examination has been shown
to be incorrect, with atherosclerotic lesions commonly being covered by an intact
endothelium.19,55 It is now more widely accepted that lesion formation is a result of
endothelial activation, in which the endothelium becomes increasingly adhesive to
circulating monocytes and T-lymphocytes, and more permeable to low density
lipoprotein (LDL).56-59
1.2.1.2 The response-to-retention hypothesis
The response-to-retention hypothesis suggests that atherosclerotic lesion
formation is mainly a result of increased uptake and retention of lipoprotein in the
vessel wall. While this is a crucial part of atherosclerosis, it is not necessarily the
most important factor. Research regarding the response-to-retention hypothesis did
shed light on the importance of various other players in the atherosclerotic disease
process though. It has been shown that lipoprotein lipase and other lysosomal and
lipolytic enzymes play an important role in sub-endothelial accumulation of
triglyceride-rich lipoproteins due to the size-restricted process of transcytosis. ’
Also, specific proteoglycans in the vessel wall, and other accompanying matrix
components play an important role in the retention of lipoproteins in the intimal space
in the early stages of atherosclerosis.24'27,31 Finally, it has been shown that once in
the intimal space, LDL particles can cluster to form aggregates, which are taken up by
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macrophages and to a lesser extent smooth muscle cells, facilitating the formation of
foam cells in the intimai layer.21’32,37’60
1.2.1.3 The oxidative modification hypothesis
The oxidative modification hypothesis suggests that atherosclerotic lesion
formation is mainly a result of oxidation of lipids, specifically those carried by LDL
particles. In atherosclerosis, macrophages in the intimai space are responsible for the
uptake of LDL particles. However, the oxidative modification hypothesis suggests
that normal LDL particles are not atherogenic per se, and that they require
modification - in this case oxidation - to increase uptake by macrophages in the
intimai space. ’

When LDL particles are oxidized, apolipoprotein B-100 can be

modified, such that its lysine residues become negatively charged, and the particles
become targeted for scavenger receptor-mediated uptake by intimai macrophages.
This contributes to the formation of cholesterol-ester filled foam cells, and
subsequently, fatty streak lesions.41,42 Minimally oxidized LDL can directly enhance
the inflammatory response45 in atherosclerosis by eliciting an increase of monocyte
chemotactic protein-1 (MCP-1) synthesis in endothelial cells and smooth muscle
cells.43,44 An increase in the presence of oxidized LDL particles can stimulate
proliferation of smooth muscle cells,11 and directly attract T-lymphocytes and
monocytes,48' 49 while increasing macrophage uptake of LDL via the formation of
immune complexes. ’ The contribution of oxidized LDL to the inflammatory
process can in turn lead to further oxidation, and therefore a cycle of oxidation and
inflammation contributes to the formation of atherosclerosis.
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1.2.2 Etiology of atherosclerosis - the inflammatory model
Atherosclerosis is initiated by vascular injury as a result of
hypercholesterolemia, high serum homocysteine levels or other insult causing
endothelial activation. This endothelial activation in turn leads to the recruitment of
immune cells to the damaged endothelium ’ ’ '

The initial immune response

involves an upregulation of leukocyte adhesion molecules like vascular cell adhesion
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) on the
endothelium that adhere to circulating monocytes recruited to take up antigenic
oxidized LDL particles in the intimal space.19,65'67 The inflammatory response
involves an upregulation of cytokines and adhesion molecules like VCAM-1 and
xo

ICAM-l to facilitate a normal healing process. '

n*\

Following adhesion to the

endothelium, monocytes migrate into the intimal space and are induced to
differentiate into macrophages by macrophage colony stimulating factor (M-CSF). At
the same time, they up-regulate expression of scavenger receptors, leading to uptake
of oxidized LDL and formation of foam cells, grouping together to form visibly
noticeable “fatty streak lesions”. 62,65,73-82
During lipid uptake and fatty streak formation, there is an augmented
inflammatory response due to the synthesis and release of further inflammatory
cytokines from immune cells in the circulation, endothelial cells and macrophages.74,
75,83 The augmented inflammatory response and cytokine release can largely be
attributed to Thl-like cells in the lesion, responsible for the synthesis and secretion of
pro-atherogenic cytokines such as interferon-y (IFN-y), interleukin-2 (IL-2),
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interleukin-12 (IL-12), Interleukin-18 (IL-18) and tumour necrosis factor-a and -P
(TNF-a/TNF-P) causing activation of macrophages and other vascular cells ,64' 84-88
Atherosclerosis is largely a cell-mediated process, facilitated by CD4+T cells,
however CD84 T cells, natural killer T (NKT) cells and B cells can be found in or
around atherosclerotic plaques, all interacting to release both pro and anti-atherogenic
on

cytokines.

Most lymphocytes in atherosclerosis are found near the unstable

shoulder area of lesions and lesions with more activated T cells than helper T cells
seem to be more susceptible to rupture, and associated complications such as
myocardial infarct or stroke.5,16,89
1.2.3 Pathogenesis of atherosclerosis - plaque formation
Following fatty streak formation, there is further lipid accumulation in the
intimal space, leading to a compensatory expansion of the blood vessel to
accommodate normal flow, followed by further plaque formation and stenosis of the
artery.13,19,65,79,90 92 It was previously thought that complications associated with
atherosclerosis were due to the degree of stenosis in the affected vessel, but it has
since been shown that the likelihood and degree of a cardiac event is more likely due
to the composition of the atherosclerotic plaque and the plaque’s vulnerability.93
During development of atherosclerotic plaques, there is formation of a fibrous
cap around a core consisting of lipid and other debris from dead macrophages. The
fibrous cap is formed as a result of smooth muscle cells moving from the media to the
intima, and taking on a “synthetic” phenotype, leading to the secretion of extracellular
matrix proteins for cap formation.94"99 Plaques are classified as vulnerable or not
based on the thickness of the cap and the overall composition of the plaque.63,91
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Plaques with thin fibrous caps often rupture as a result of increased proteinase
expression and action. The proteinase action helps to break down the smooth muscle
cell derived extracellular matrix comprising the cap, making it more susceptible to
rupture.13' 16,100 ,05 Plaque rupture can lead to formation of a thrombus, occluding the
affected vessel or possibly breaking off and causing occlusion in a downstream
vessel.106' 110
1.2.4 Current Treatments and associated issues
It is critical to find more effective preventive and interventional treatments to
reduce the incidence of atherosclerosis in both the developed and the developing
world. Several interventional therapies for atherosclerosis have proven to be effective,
including drugs such as statins - HMG-CoA Reductase inhibitors - with lipid
lowering and anti-inflammatory effects, recently showing promise as a prophylactic
treatment for atherosclerosis as well as a therapeutic treatment.111"113 Statins were
originally developed with a focus on their lipid-lowering effects, but it has since been
found that they may also up-regulate expression of endothelial Nitric Oxide Synthase
(eNOS) which attenuates the inflammatory response and limits the initiation of
atherosclerosis.111 However, statins have been shown on occasion to have
detrimental side effects making their long-term use somewhat undesired.114 Some
observed side effects include increased chance of hemorrhagic stroke, and more
commonly, muscle pain known as “statin-induced myopathy”.
Other drugs such as angiotensin converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) have also been shown to improve
cardiovascular patient prognoses, with recent evidence also pointing to anti-oxidant
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and anti-inflammatory effects.115 However, ACE inhibitors have been shown to
induce dizziness, low blood pressure, kidney defects, and angioedema,116’117 and
ARBs have been shown to induce cough and angioedema but to a lesser extent than
ACE inhibitors.116 Therefore, finding a safe and effective alternative therapy is an
important step in the search for an ideal treatment for atherosclerosis.

1.3 GINSENG
Ginseng is a natural health supplement used for thousands of years for its
healing potential, and “adaptogenic” capabilities, increasing the body’s defense
against stress, fatigue and anxiety in a non-specific, non-toxic and normalizing
manner.118 Previous studies have shown promising results of ginseng treatment in
attenuating inflammation,119"124oxidation,120' 125-134 and high serum lipid and
cholesterol levels.123,135-140 Therefore, ginseng appears to be a good candidate for
further studies in the treatment of atherosclerosis to help provide mechanistic data,
and the opportunity for more specific information on its use as a therapeutic for
atherosclerosis or other vascular complications.
There are several different species of ginseng, the most commonly studied and
used being Panax ginseng (Asian ginseng) and Panax quinquefolius (North American
ginseng).119 It is well accepted that the active ingredients in ginseng extracts are
ginsenosides, which are molecules known as triterpene saponins that have a rigid 4ring steroidal structure. There have been over 30 ginsenosides identified, each with
different pharmacological effects and the most commonly studied are Rbl and Rgl,
which have been reported to act through glucocorticoid receptors. In addition to
ginsenosides, there are a number of other components in ginseng extracts with
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potential pharmacological effects, most notably a polysaccharide component that has
been suggested to have immunomodulating capabilities.141 Azike et al. (2011)
analyzed the effect of different processing techniques to determine the effect of
alcohol or aqueous extraction on ginsenoside profile of extracts. They found that an
alcohol extract had more than twice as much ginsenoside as an aqueous extract, while
also showing a higher Rb 1/Re ratio than an aqueous extract. In addition, alcohol
extracts had no polysaccharide component, suggesting some inconsistencies in the
literature with regard to the immunomodulating capabilities of ginseng.142
In addition, the effects of ginseng may be even more complex, as ginsenosides
may act either through a non-genomic, or genomic pathway. The non-genomic
pathway suggests that due to the amphiphilic nature of ginsenosides they may be able
to intercalate cell membranes, altering fluidity or cell-signalling, and that their
steroidal structure may allow for interactions with cell membrane receptors or steroid
receptors in the cytoplasm, leading to an immediate change in protein expression in
the cell. The genomic pathway suggests that ginsenosides may in fact interact
directly with genetic response elements in the nucleus, causing a slower response
caused by an alteration of transcription.119
Finally, despite many similarities, different adaptogenic herbs have different
ginsenoside profiles. Specifically, Panax quinquefolius (North American ginseng)
tends to have a much higher Rbl/Rgl and Rbl/Rb2 ratio than Panax ginseng (Asian
ginseng) while also typically having very low levels of Rf. The ginsenoside profile of
different extracts can quite easily be determined using a variety of biochemical
techniques.1The major difference between this and previous studies is that this study
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will critically examine the effects of aqueous and ethanol extracts of North American
Ginseng (Panax quinquefolius) while earlier studies examined other similar
adaptogenic herbs such as Asian Ginseng (Panax ginseng), pseudoginseng (Panax
notoginseng) or Korean Ginseng (Panax schinsen).
1.3.1 Anti-inflammatory effects
Previous studies on the anti-inflammatory effects of ginseng show that
ginseng is capable of attenuating the inflammatory response seen in atherosclerosis
by several different means. Ling et al. (2008) showed that human vascular
endothelial cells treated with 100 pg/mL of ginseng extract, showed a significant
reduction of VCAM-1 expression as compared with a positive control, following
inflammatory stimulation with 30 ng/mL of TNF-a.121 Wan et al. (2009) verified this,
while also showing a significant reduction in TNF-a induced expression of ICAMl .122 They also looked at the effect of ginseng treatment on monocyte adhesion to
endothelial cells, and showed ginseng in a dose-dependent manner was capable of
significantly reducing monocyte adhesion at doses of 100 pg/mL and 300 pg/mL.
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Using the apoE-knockout mouse, Wan et al. (2009) also assessed the effects of
ginseng treatment in vivo. Using an Enzyme-Linked Immunosorbent Assay, they
showed decreased serum levels of pro-inflammatory cytokines, such as TNF-a and
IL-6 in ginseng-treated animals.122
Another group used a rat model in which rats were fed a high-fat diet, and an
inflammatory response was induced via injection of Zymosan A.

They looked

downstream of TNF-a, at the expression of transcription factor, NF-kB’s p65 subunit,
and its inhibitor, iKBa. The found that while Zymosan-induced inflammation led to

12

an increase of NF-kB expression, and decrease of IkBu expression - favouring an
inflammatory response - treatment with 100 mg/kg/day of ginseng significantly
attenuated this response, returning expression levels to control-like values.

They

also looked at RNA levels of inflammatory markers, and found that ginseng reduced
expression of integrins, IL-18, IL-ip, and matrix metalloproteinases (MMPs) 2 and 9
compared with the Zymosan treated group.

The above results provide compelling

evidence that ginseng reduces the inflammatory response both in vitro and in vivo,
warranting further work, especially in a system modeling atherosclerosis for our
purposes.
1.3.2 Anti-oxidative effects
Another connection between ginseng and atherosclerosis is the anti-oxidant
capability of ginseng. Early studies, as reviewed by Gillis (1997) indicated ginseng
has a cardio-protective effect through anti-oxidant action, although the mechanism
was not certain.

Li et al. (1999) examined the effects of ginseng treatment on

cultured cardiac myocytes from rats. They showed ginseng treatment was able to
reduce lipid peroxidation - a major factor in atherosclerosis - significantly, using
techniques which measured the amount of thiobarbituric acid reactive substances
(TBARS) in the media following oxidation induced by copper sulfate.

They also

looked at the effect of lipid peroxidation on endothelium-dependent relaxation in
aortic rings, and found that ginseng treatment was able to significantly relieve
impairment of endothelial-dependent relaxation caused by high levels of oxidized
LDL.

This shifted much of the focus regarding ginseng’s antioxidant capabilities

to studies on nitric oxide and the vasodilatory properties of ginseng. Most research

surrounding the antioxidant effects of ginseng suggest an increase in nitric oxide
levels, a response normally down-regulated following free-radical damage caused by
reactive oxygen species.

Rimar et al. (1996) showed that following free radical

production in response to electrolysis, raw ginseng extract and artificially digested
ginseng extract were capable of restoring acetylcholine-induced vasodilation in
pulmonary vasculature.132 Limited mechanistic data exists regarding the increased
nitric oxide availability seen with ginseng treatment, but Kim et al. (2007) showed
that this effect is most likely occurring via the PI3K/Akt pathway, leading to
increased phosphorylation of eNOS and release of nitric oxide.143
1.3.3 Lipid-lowering effects
Along with anti-inflammatory and anti-oxidant effects, ginseng has been
shown to have lipid-lowering effects, with several studies showing that ginseng
treatment leads to a decrease in serum total cholesterol, serum total triglycerides,
LDL levels and an increase in HDL levels.123’137,138 Kim and Park (2003) studied the
anti-oxidant and lipid-lowering effects of ginseng in humans, measuring serum
cholesterol, malondialdehyde (MDA), superoxide dismutase (SOD) and catalase
levels, the latter three as measures of reactive oxygen species. They found ginseng
decreased MDA levels, and increased SOD and catalase levels, confirming the anti
oxidant effects of this food supplement. They also showed ginseng was capable of
decreasing serum total cholesterol and triglycerides, decreasing serum LDL levels
and increasing HDL levels. The mechanism was not confirmed, but based on previous
studies, they speculate that these effects are most likely by increased cholesterol
turnover through degradation and excretion as bile acids.

Other studies show
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similar results, but via alternative mechanisms, such as increased fatty acid synthetase
(FAS) activity or increased expression of the LDL receptor gene via sterol regulatory
element binding proteins (SREBPs) in both hepatocytes and adipocytes.

These

lipid lowering effects of ginseng could prove very useful in reducing a patient’s risk
of further atherosclerotic progression.

1.4 RATIONALE FOR THE STUDY
The literature suggests that ginseng holds promise as an alternative therapy for
the prevention and treatment of atherosclerosis. Atherosclerosis is a complex disease,
but by acting on three main aspects of atherosclerosis; inflammation, oxidation and
high serum cholesterol, ginseng seems like a viable alternative or addition to existing
pharmaceuticals. It is also promising, that even within these three aspects of
atherosclerosis, ginseng may act on multiple pathways. A single treatment with such
a wide range of effects could prove invaluable, particularly with limited side effects
seen with ginseng administration. Through in vitro and in vivo experiments as
outlined below, we will determine the efficacy of ginseng treatment in the
atherosclerotic disease process, and in the future, attempt to further elucidate
mechanisms by which ginseng is capable of attenuating atherosclerosis. This will
promote the formulation of therapies for people both at risk for or suffering from
atherosclerosis.

1.5 OBJECTIVES
The main objective was to critically assess the effects of ginseng administration
on the initiation and progression of atherosclerosis. To do this, an in vitro model,
followed by in vivo experiments in rats - an established short-term model - and
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rabbits - an established long-term model - were employed. The importance of such a
study is that ginseng, a natural health product currently sold as a dietary supplement,
may attenuate pathological processes involved in the formation of atherosclerotic
lesions. Unlike current pharmaceutical treatments for atherosclerosis however,
ginseng can safely be taken by healthy individuals, and may prove to be an effective
preventative measure to avoid complications associated with atherosclerosis, or
possibly a safe interventional treatment compared to currently available therapies.
Objective 1: In vitro studies
The in vitro studies focused on the inflammatory aspect of atherosclerosis, and
were carried out using primary cultures of porcine aortic endothelial cells. These
experiments examined the potential anti-inflammatory effects of ginseng pretreatment
prior to stimulation with interleukin-1P (IL-ip) - a common inflammatory cytokine in
atherosclerosis. These experiments provided an in vitro model for examining the
effects of North American ginseng treatment on inflammation-associated ICAM-1
and VCAM-1 expression, one of the first steps in the initiation of atherosclerotic
lesion formation. This study also provided preliminary data prior to the rat studies,
where similar effects were anticipated.
Objective 2: Rat studies
High Cholesterol Diet
The rat studies built on the in vitro work, focusing on the effects of ginseng
administration on inflammation, specifically monocyte adhesion. Long Evans rats
were used in an established model of atherosclerosis effectively allowing the early
detection of atherosclerotic lesion initiation.144

16

High Homocysteine Diet
Similar to the high cholesterol study, the homocysteine study looked at the
effects of ginseng on monocyte adhesion, but in response to another common
atherosclerotic risk factor, high homocysteine levels. An examination of the effects of
ginseng treatment on inflammation in an in vivo model using two different
atherogenic factors may lead to a better understanding of ginseng’s therapeutic
potential in atherosclerosis.
Objective 3: Rabbit studies
The long-term rabbit study allowed assessment of the effects of ginseng
administration on the initiation, progression and later stages of atherosclerosis,
including lipid accumulation and plaque formation. The rabbit study provided a
paradigm to assess timing of ginseng administration, as well as its efficacy in
attenuating atherosclerosis. Since healthy people can take ginseng, it is critical to
know if there are any preventive effects, such that people in at-risk groups for
atherosclerosis may begin a treatment regimen before experiencing a cardiac event.
Rabbits provide an effective model for this study, forming human-like lesions when
fed low levels of cholesterol for long periods of time.145,146
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1.6 HYPOTHESES
In vitro studies
Ginseng will reduce IL-l(3-induced expression of VCAM-1 and ICAM-1 in porcine
aortic endothelial cells, suggesting it may be a viable alternative to current anti
inflammatory and anti-atherogenic treatments.
Rat studies
Daily ginseng administration will reduce monocyte adhesion to the aortic
endothelium in rats fed either a high cholesterol or high homocysteine diet.
Rabbit studies
Ginseng will reduce lesion initiation by reducing serum total cholesterol levels, and
decreasing lipid deposition and plaque formation. Ginseng will alter lesion
progression, by changing lesion composition, such that it encourages stabilization in
the aorta of cholesterol-fed New Zealand White rabbits.

\
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CHAPTER 2

THE EFFECTS OF NORTH AMERICAN GINSENG ON THE
INITIATION OF ATHEROSCLEROSIS IN VITRO AND IN VIVO

2.1 INTRODUCTION
There is a large body of research examining the effect of ginseng on various
aspects of atherosclerosis, including inflammation, oxidation, and high serum
cholesterol levels. For this project, the effects of North American ginseng extract on
the initiation of atherosclerosis were studied using an in vitro model of inflammation
in porcine aortic endothelial cells, as well as an in vivo model of monocyte adhesion
in the rat. The rat model also allowed an analysis of the potential lipid-lowering
effects of North American Ginseng in a short-term administration paradigm.
Although there are current existing therapies for atherosclerosis, including
statins,1Angiotensin Converting Enzymes (ACEs) and Angiotensin Receptor
Blockers (ARBs), there are still associated complications with these treatments,
including statin-induced myopathy,3 dizziness, kidney defects and angioedema.4,5
This creates a need for a safe and effective alternative or addition to existing
therapeutic regimens to limit the burden of atherosclerosis.
Previous studies indicate that ginseng has the potential to be used as both a
prophylactic and therapeutic treatment for atherosclerosis based on several of its
properties. First, ginseng has been shown to have anti-inflammatory effects. The
literature suggests that ginseng may be acting on a number of different pathways in
the body, potentially attenuating the inflammatory response at the level of
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inflammatory cytokine production,6 expression of adhesion molecules such as
vascular cell adhesion molecule-1 (VCAM-1) or intercellular adhesion molecule-1
(ICAM-l) on the activated endothelium,

H Q

or having a direct effect on various

/

molecular pathways via interaction with steroid receptors or alteration of transcription
factor expression.9 The in vitro component of this study will look at the ability of
aqueous and ethanol ginseng extracts to limit the increased expression of VCAM-1
and ICAM-l following inflammatory stimulation with interleukin-1(3.
Ginseng has also been shown to have potential anti-oxidant properties,10' 12
also promising in the treatment of atherosclerosis, as low density lipoprotein (LDL)
particles are modified - typically oxidized - in the intimal space of a vessel, and are
taken up by macrophages via scavenger-receptor interactions.

Finally, previous

research indicates ginseng may be capable of lowering serum lipid levels, specifically
lowering serum total cholesterol and LDL cholesterol.9,14,15 The short-term rat study
will also look at the potential lipid-lowering effects of ginseng, as blood will be
collected at sacrifice, and serum total cholesterol will be measured.
The major difference between this and previous studies is that this study will
examine the effects of North American Ginseng, or Panax quinquefolius, while
earlier studies examined similar adaptogenic herbs like Asian Ginseng (Panax
ginseng), or other related species like pseudoginseng {Panax notoginseng).
Traditional Chinese Medicine suggests that there is a balance between forces in the
body, specifically between Yin and Yang and that it is this balance that allows a
person to be healthy. The two are traditionally seen as having opposite characteristics,
for example, Yin representing cooling, dark, female and negative, and Yang
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representing hot, sunshine, male and positive. Traditionally, it is thought that Asian
ginseng tends to exert Yang properties when taken, and North American Ginseng Yin
properties.,ft Different conditions are defined as the result of either an excess or
deficiency of yin or yang. For example, Diabetes Mellitus is commonly considered to
be a result of a Yin deficiency and therefore should be treated with something with
Yin characteristics, like North American Ginseng.17
With an exaggerated inflammatory response, atherosclerosis could potentially
be considered a condition resulting from an excess of Yang. North American
Ginseng expressing the cooling properties of Yin, could be an ideal candidate for
attenuating atherosclerosis by limiting the inflammatory response. This ‘cooling’
response may be effective in limiting reactive oxygen species formation, decreasing
oxidation and therefore uptake of LDL cholesterol by macrophages in the intimal
space. This study looked to determine if North American Ginseng is capable of
effectively attenuating inflammation and the initiation of atherosclerosis both in
culture with porcine aortic endothelial cells as well as in hypercholesterolemic and
hyperhomocysteinemic rat models. This study used both an aqueous and an ethanol
extract of North American ginseng to see if either extract was effective in attenuating
the initiation of atherosclerosis, and whether a higher polysaccharide or ginsenoside
content is more beneficial in the case of inflammation and monocyte adhesion. 18
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2.2 MATERIALS AND METHODS
2.2.1 Cell Culture System
2.2.1.1 Tissue C ollection
Porcine hearts were retrieved shortly after sacrifice from the Mt. Brydges
Abattoir (Mt. Brydges, Ontario). Hearts were transported on ice, in a mixture of
HBSS, 0.2% Amphotericin B and 1% Penicillin/Streptomycin (all from Invitrogen
Canada, Burlington, ON) to sterile lab conditions, and a piece of aorta immediately
proximal to the heart was removed from each.
2.2.1.2 Cell Culture
Outside of the tissue culture hood, aortas were cleaned of adventitia and
surrounding tissue using forceps and scissors while avoiding compression of the aorta.
Aortas were severed above the first intercostal ostia and at the beginning of the aortic
arch and cut into sections approximately 2-3 cm long. Pieces of aorta were
submerged in Media-199, 1% penicillin, 1% streptomycin and 0.2% amphotericin B
(Invitrogen Canada, Burlington, ON) for 5 minutes. Pieces were removed from the
solution, placed into a sterile Petri dish using sterilized forceps and transferred into
tissue culture hood.
Inside the tissue culture hood, pieces were flushed with HBSS (Invitrogen
Canada, Burlington, ON) solution. Sterile hemostats were used to seal one end of
each aortic piece in a separate Petri dish. The aorta ‘cups’ were filled with a solution
composed of HBSS (Invitrogen Canada, Burlington, ON) and 0.25% collagenase
(Sigma-Aldrich Canada, Mississauga, ON). A sterile beaker was used as a lid to
cover the cups and sections were incubated at 37°C for 10 minutes. Sections were
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removed from the incubator, and using a lmL pipette, the HBSS/Collagenase solution
from aortic cups was transferred into a sterile Falcon tube. The cups were rinsed
again 4 times using a solution of RPMI-1640/FBS/P/S/Amp B. This solution was
then transferred into the same sterile Falcon tube used in the above step. The falcon
tube was centrifuged at 1250 RPM for 5 minutes, and the pellet was re-suspended in 2
mL of RPMI-1640/FBS/P/S/Amp B. The cells were then transferred into a 35 mm
petri dish and 2 mL of sterile RPMI-1640/FBS/P/S/Amp B solution was added. The
cells were then incubated at 37°C and 5% CO2; Media was not changed until
sufficient cellular outgrowth was visible.
2.2.1.3 Inflammation and Ginseng Treatment
Following growth to confluence, cells were seeded on coverslips in 6-well
plates in Dulbecco’s Modified Eagle Medium (DMEM) with 10% Fetal Bovine
Serum (FBS), 1% Penicillin/Streptomycin (P/S) and 1% glutamine (all Invitrogen
Canada, Burlington, ON) for later assessment via confocal microscopy. An
inflammatory response was stimulated with recombinant human IL-ip (Peprotech,
Rocky Hill, NJ) and following fixation with ice-cold methanol, cells were stained for
vascular cell adhesion molecule-1 (VCAM-1) with primary antibody, Rabbit
polyclonal IgG H-276 (Santa Cruz Biotechnology, Santa Cruz, CA) or intercellular
adhesion molecule-1 (ICAM-1) with primary antibody, Rabbit polyclonal IgG H-108
(Santa Cruz Biotechnology, Santa Cruz, CA), followed by secondary antibody, Alexa
Fluor® 488 goat anti-rabbit IgG (H+L) (Invitrogen Canada, Burlington, ON) and
nuclei were stained with Hoechst 33342 (Sigma Aldrich Canada, Oakville, ON).
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Samples were then assessed in triplicate, looking at five fields of view per replicate,
using a Zeiss LSM 410 confocal microscope (Zeiss Canada, Toronto, ON).
Cells were treated with 10 ng/mL of IL-ip, a concentration found previously
in our lab to stimulate an inflammatory response in endothelial cells,19 and were
pretreated with ginseng at four concentrations - 50, 125 and 250, and 500 pg/mL
.

.

.

1

(Figure 2.1). In accordance with previous studies, ginseng extract was added to the
growth media for twenty-four hours, after which an inflammatory response was
induced with IL-1(3 for four hours. The cells were then fixed, and VCAM-1 and
ICAM-1 expression was assessed as described above. Controls consisted of cells with
no treatment, IL-lp alone, or 125 pg/mL aqueous or ethanol ginseng extract alone
with no IL-1/3 stimulation.
To determine the effects of long-term pretreatment and repeated
administration, cells were also pre-treated with ginseng for 5 days prior to
inflammatory stimulation. To avoid complications due to extensive cell growth and
proliferation during this period, cells were grown in low serum conditions (0.4%
FBS). All samples were then fixed and stained for assessment via confocal
microscopy as described above.
The ginseng extracts used were those characterized by Azike et al. (2011) and
used by Chakrabarti et al. (2011) and Feng et al. (2011).20'22

Figure 2.1 Summary of experimental design for in vitro experiments.
Treatment of 6-well plates for a single replicate of the in vitro study examining the
effects of aqueous and ethanol North American ginseng extract on IL-lp induced
inflammatory-associated expression of VCAM-1 and ICAM-1 is illustrated. Cells
were stained for either VCAM-1 or ICAM-1 in a single replicate as shown here.
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2.2.1.4 Toxicity of Ginseng Extract
To confirm that the ginseng extract was not cytotoxic to the porcine aortic
endothelial cells, an MTT Assay CGD-1 Kit (Sigma-Aldrich, Mississauga, ON) was
used (Data not shown). The MTT assay provides a measure of metabolic activity of
these cells, and therefore is often used as an indirect measure of cell viability.23,24
2.2.1.5 Cell Phenotyping
Cell morphology was assessed to ensure that the cell culture procedure
properly isolated aortic endothelial cells. Cells examined on the confocal microscope
showed a “cobblestone” pattern typical of an endothelial monolayer in culture.25
2.2.2 Rat Experiments
2.2.2.1 High Cholesterol D iet
To assess the effects of ginseng extract on monocyte adhesion in vivo, Long
Evans rats were fed an established atherogenic diet for 17 days.24 The atherogenic
diet consisted of normal chow plus 4% cholesterol, 1% cholic acid, and 0.5%
propylthiouracil, the combination of which will increase serum cholesterol levels,
particularly in the LDL fraction, favoring cholesterol transport to the periphery, rather
than to the liver for excretion. Previous studies have shown that rats maintained on
this diet developed early stage atherosclerotic lesions as characterized by monocyte
binding to the endothelium.24
2.2.2.1.1 Ginseng Administration
Rats were pre-treated for 38 days with 0 (0.9% saline), 125 or 250 mg/kg/day
ethanol ginseng extract (n=10, 9, and 11, respectively). Ginseng administration
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continued for another 17 days coinciding with atherogenic diet feeding. Ginseng
extract was administered by oral gavage daily.
The ginseng extracts used were those characterized by Azike et al. (2011) and
used by Chakrabarti et al. (2011) and Feng et al. (2011).20'22
2.2.2.1.2 Serum Cholesterol
Following the treatment period, rats were sacrificed with CO2 . Blood was
collected by intracardiac puncture, transferred to 15mL tubes containing 200 pL of
0.3% EDTA, inverted and placed on ice. Blood was centrifuged at 5000 RPM for 10
minutes at room temperature to separate plasma from cellular components. Plasma
was collected with a transfer pipette, placed into 2mL cryotubes tubes, and frozen at 20°C until analyzed.
To analyze serum total cholesterol levels, plasma samples were thawed, and
the Serum E Cholesterol Kit (Wako Diagnostics, Richmond, VA) colorimetric assay
was used. Absorbance at 600 nm was measured using an Omega series micro-plate
reader (BMG Labtech, Ortenberg, Germany) and correlating plasma cholesterol
levels (in mg/dL) were determined using a standard curve.
2.2.2.2

High M onocysteine D iet

Male Sprague-Dawley rats were block-random assigned into 8 groups (n=8),
named based on daily treatments, and all groups remained on normal chow for the
duration of the experiment (Table 1). Groups received respective treatments by daily
oral gavage for 6 weeks, and were euthanized with CO2 .

Table 1. Summary of experimental design for hom ocysteine-induced
monocyte adhesion rat study. Male Sprague-Dawley rats were block-random
assigned into 8 groups (n=8), named based on daily treatments, and all groups
remained on normal chow for the duration of the experiment. Groups received
respective treatments by daily oral gavage for 6 weeks, and were euthanized with
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Abbreviated
Treatment Group
C
H
AL
AH
HAL
HAH
OL
OH
HOL
HOH

Treatment
Control - normal diet
50 mg/kg/day homocysteine
125 mg/kg/day aqueous ginseng extract
500 mg/kg/day aqueous ginseng extract
Hey + AL
Hey + AH
125 mg/kg/day ethanol ginseng extract
500 mg/kg/day ethanol ginseng extract
Hey + OL
Hey + OH
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2.2.2.3 Monocyte A dhesion Assay
In both the high cholesterol and high homocysteine studies, the rats were perfusion
fixed using 4% paraformaldehyde. Consistent with an established method, the
thoracic aorta was removed, cut longitudinally and stained with Oil Red O (Sigma
Aldrich Canada, Oakville, ON) to detect intracellular lipid and Hoechst 33342 (Sigma
Aldrich Canada, Oakville, ON) to detect nuclei.24 Monocytes differ from the
underlying endothelium with respect to both the round shape of their nuclei as well as
the intensity of Hoechst staining (Figure 2.2). Three sections from each rat were
whole mounted, viewed en face using a Zeiss Axioplan 2IE fluorescent microscope
(Carl Zeiss Canada, Toronto, ON) and monocytes bound were counted in 5 different
fields of view per section. Each high-powered field of view had an area of
9.32x104pm2, which will be referred to as a high-powered field (HPF).

Figure 2.2 Sample monocyte adhesion assay im age. Shown here are an
example of a relatively normal aorta (left) and a heavily diseased aorta (right), in
which there are a large number of monocytes bound to the endothelium (shown with
red arrows). (Scale bar = 50 pm)
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2.2.2.4 Statistical Analysis
Data is expressed as median ± interquartile range and statistically analyzed
using a Kruskal-Wallis Test for nonparametric data, and a Dunn’s Multiple
Comparison Post Test was used to compare all pairs of groups. All analyses were
done using GraphPad Prism (V5, GraphPad Software, Inc., La Jolla, CA). P-values
less than 0.05 are be considered significant.

2.3 RESULTS
2.3.1 Cell Experiments
Cells treated with IL-ip expressed higher levels of ICAM-1 compared to
untreated controls (Figures 2.3 A and 2.3 B). With a 24-hour pretreatment, it
appeared that 50 pg/mL or 250 pg/mL of ethanol ginseng extract was able to limit
ICAM-1 expression (Figure 2.3 D/H respectively) while treatment with the aqueous
extract (Figure 2.3 C/E/G) or 125 pg/mL ethanol extract (Figure 2.3 F) did not appear
to have any noticeable effect. Interleukin-ip treatment induced VCAM expression,
\

but to a lesser extent (Figures 2.4 A and 2.4 B) and pretreatment of cells with all three
doses of either ethanol or aqueous extract appeared to attenuate VCAM-1 expression
in these cultures (Figure 2.4).
When pretreated for 5 days, it appeared that both the aqueous and ethanol
extracts were able to somewhat reduce IL-ip induced expression of ICAM-1 at both
50 pg/mL (Figure 2.5 C/D respectively) and 500 pg/mL (Figure 2.5 I/J respectively)
however treatment with 125 pg/mL (Figure 2.5 E/F) or 250 pg/mL (Figure 2.5 G/H)
did not appear to have a noticeable effect. However, only the higher dose of the
ethanol extract was effective in reducing VCAM-1 (Figure 2.6J), while all other
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treatments appeared unable to alter VCAM-1

expression (Figure 2.6C-I).

Furthermore, it appeared that IL-lp stimulation of either ICAM-1 (Figure 2.3B and
2.5B) or VCAM-1 (Figure 2.4B and 2.6B) expression after 5 days in culture had less
robust of an effect on than cells stimulated after 24 hours. It is important to note that
in all cell experiments, though there may have appeared to be a difference in
expression with certain treatments, the data could not be quantitated to substantiate
the difference.
The addition of either ginseng extract to the growth media had no effect on
cell metabolism or viability as was measured using an MTT assay (Figure 2.7).

Figure 2.3 Low and high doses o f ethanol ginseng extract reduced ILip induced ICAM-1 expression with 24-hour pretreatment as seen
using im m unofluorescence. Porcine aortic endothelial cells were pretreated for
24 hours with various concentrations of aqueous or ethanol extracted ginseng.
Following pretreatment, cells were incubated in 10 ng/mL of IL-lp for 4 hours, fixed
and analyzed for ICAM-1 expression using immunofluorescent confocal microscopy.
Nuclei were detected using Hoechst 33342. (A) Untreated cells; (B) Cells treated
with IL-ip alone; (C )/(D ) Cells treated with IL-ip and 50 pg/mL aqueous or ethanol
ginseng extract respectively; (E)/(F) Cells treated with IL-ip and 125 pg/mL
aqueous or ethanol ginseng extract respectively; (G )/(H ) Cells treated with IL-ip
and 250 pg/mL aqueous or ethanol ginseng extract respectively. Results presented are
representative of 3 replicates (Scale Bar = 50 pm).
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Figure 2.4 All doses of aqueous and ethanol ginseng extract reduced
IL -ip induced VCAM-1 expression with 24-hour pretreatment as seen
using im munofluorescence. Porcine aortic endothelial cells were pretreated for
24 hours with various concentrations of aqueous or ethanol extracted ginseng.
Following pretreatment, cells were incubated in 10 ng/mL of IL-ip for 4 hours, fixed
and analyzed for VCAM-1 expression using immunofluorescent confocal microscopy.
Nuclei were detected using Hoechst 33342. (A) Untreated cells; (B) Cells treated
with IL-ip alone; (C )/(D ) Cells treated with IL-lp and 50 pg/mL aqueous or ethanol
ginseng extract respectively; (E)/(F) Cells treated with IL-ip and 125 pg/mL
aqueous or ethanol ginseng extract respectively; (G)/(H) Cells treated with IL-ip
and 250 pg/mL aqueous or ethanol ginseng extract respectively. Results presented are
representative of 3 replicates (Scale Bar = 50 pm).
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Figure 2.5 Five day pretreatment with low and high doses of aqueous
or ethanol ginseng extract reduced IL -lp induced ICAM-1 expression
as seen using im m unofluorescence. Porcine aortic endothelial cells were
pretreated for 5 days with various concentrations of aqueous or ethanol extracted
ginseng. Following pretreatment, cells were incubated in 10 ng/mL of IL-ip for 4
hours, fixed and analyzed for ICAM-1 expression using immunofluorescent confocal
microscopy. Nuclei were detected using Hoechst 33342. (A) Untreated cells; (B)
Cells treated with just IL-IP; (C)/(D ) Cells treated with IL-ip and 50 pg/mL
aqueous or ethanol ginseng extract respectively; (E)/(F) Cells treated with IL-ip and
125 pg/mL aqueous or ethanol ginseng extract respectively; (G)/(H) Cells treated
with IL-ip and 250 pg/mL aqueous or ethanol ginseng extract respectively; (I)/(J)
Cells treated with IL-ip and 500 pg/mL aqueous or ethanol ginseng extract
respectively. Results presented are representative of 3 replicates (Scale Bar = 50 pm).
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Figure 2.6 Five day pretreatment with high dose ethanol ginseng
extract reduced IL -ip induced VCAM-1 expression as seen using
im munofluorescence. Porcine aortic endothelial cells were pretreated for 5 days
with various concentrations of aqueous or ethanol extracted ginseng. Following
pretreatment, cells were incubated in 10 ng/mL of IL-1P for 4 hours, fixed and
analyzed for VCAM-1 expression using immunofluorescent confocal microscopy.
Nuclei were detected using Hoechst 33342. (A) Untreated cells; (B) Cells treated
with just IL-1|3; (C )/(D ) Cells treated with IL-1p and 50 pg/mL aqueous or ethanol
ginseng extract respectively; (E)/(F) Cells treated with IL-1J3 and 125 pg/mL
aqueous or ethanol ginseng extract respectively; (G )/(H ) Cells treated with IL-1p
and 250 pg/mL aqueous or ethanol ginseng extract respectively; (I)/(J) Cells treated
with IL-ip and 500 pg/mL aqueous or ethanol ginseng extract respectively. Results
presented are representative of 3 replicates (Scale Bar = 50 pm).
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Figure 2.7A Aqueous ginseng extract does not significantly alter cell
metabolism and viability in culture as measured by an MTT assay.
Results shown are the absorbance values (median ± interquartile range) from MTT
assays where porcine aortic endothelial cells were grown for 24 hours in either
normal DMEM growth media, or media containing either 50, 125, or 250 ug/mL
aqueous ginseng extract. Experiments were repeated in triplicate, and no significant
difference was seen between the groups.

Figure 2.7B Ethanol ginseng extract does not significantly alter cell
metabolism and viability in culture as measured by an MTT assay.
Results shown are the absorbance values (median ± interquartile range) from MTT
assays where porcine aortic endothelial cells were grown for 24 hours in either
normal DMEM growth media, or media containing either 50, 125, or 250 ug/mL
ethanol ginseng extract. Experiments were repeated in triplicate, and no significant
difference was seen between the groups.
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2.3.2 The effect of ethanol extract of North American ginseng on
monocyte adhesion and serum total cholesterol in a
hypercholesterolem ic rat model.

The effect o f ethanol extract o f North A merican ginseng on monocyte adhesion in a
hypercholesterolemic rat model - The number of monocytes/HPF was not
significantly different (p=0.096) between rats receiving saline, or either 125
mg/kg/day or 250 mg/kg/day of ethanol ginseng extract. However, saline treated rats
appeared to have the most extensive monocyte adhesion while there was an emerging
trend that increasing doses of ethanol extract appeared to reduce the number of bound
monocytes. Rats receiving 125 mg/kg/day ethanol extract appeared to have fewer
monocytes bound than saline treated rats, while rats receiving 250 mg/kg/day
appeared to have even fewer monocytes bound (Figure 2.8A), although the difference
was not significant.
The effect o f ethanol extract o f North A merican ginseng on serum total cholesterol
levels in a hypercholesterolemic rat model - Serum total cholesterol levels were not
significantly different between rats fed a hypercholesterolemic diet and receiving
daily oral gavage of either saline, 125 mg/kg or 250 mg/kg ethanol ginseng extract
(Figure 2.8B).

Figure 2.8A Ethanol ginseng extract does not significantly affect
monocyte adhesion in hypercholesterolemic rats. Results shown are the
number (median ± interquartile range) of monocytes bound to the aortic endothelium
in a single high-powered field of view, counted based on morphologically distinct
nuclei stained with Hoechst, and observed using a Zeiss Axioplan 2IE fluorescent
microscope. Eight rats per treatment, 3 sections per rat and 5 fields per section were
analyzed.

Figure 2.8B Ethanol ginseng extract does not significantly affect serum
total cholesterol levels in hypercholesterolem ic rats. Serum cholesterol
levels (median ± interquartile range) following 17 days on hypercholesterolemic diet.
Measurements were done using the Cholesterol E assay kit from Wako Diagnostics to
measure serum total cholesterol level. Eight rats per treatment and 2 samples per rat
were analyzed.
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2.3.3 The effect of North American
hyperhomocysteinem ic rat model

ginseng

extract

The

monocyte

adhesion

effect
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ginseng
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a
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hyperhomocysteinemic rat model - Rats on a normal diet maintained a low level of
monocyte adhesion to the aortic endothelium (Figure 2.9).

The addition of

homocysteine to their diet caused a significant increase in number of monocytes
bound to the aortic endothelium. Rats treated with either aqueous (Figure 2.9A) or
ethanol (Figure 2.9B) ginseng extract at either dose did not have significantly higher
monocyte adhesion than rats on a normal diet. Rats treated with 125 or 500 mg/kg
ethanol ginseng extract in addition to a high homocysteine diet continued to have
significantly higher monocyte adhesion than rats fed normal chow (Figure 2.9A).
However, rats no longer had significantly more monocyte adhesion than rats fed a
normal diet when treated daily with 125 or 500 mg/kg/day aqueous ginseng extract
(Figure 2.9B).
\

Figure 2.9A Ethanol ginseng extract had no effect on hom ocysteineinduced monocyte adhesion in rats. Results shown are the number (median ±
interquartile range) of monocytes bound to the aortic endothelium in a single highpowered field of view, counted based on morphologically distinct nuclei stained with
Hoechst, and observed using a Zeiss Axioplan 2IE fluorescent microscope. C-control
(normal chow), OL-125 mg/kg/day ethanol extract; OH-500 mg/kg/day ethanol
extract; H-50 mg/kg/day homocysteine; HOL-50 mg/kg/day homocysteine + 125
mg/kg/day ethanol extract; HOH-50 mg/kg/day homocysteine + 500 mg/kg/day
ethanol extract. (**: p<0.001, *: p<0.05)

Figure 2.9B Rats treated with aqueous ginseng extract no longer had
significantly higher levels of monocyte adhesion than control rats.
Results shown are the number (median ± interquartile range) of monocytes bound to
the aortic endothelium in a single field of view (345 pm x 272.5 pm), counted based
on morphologically distinct nuclei stained with Hoechst, and observed using a Zeiss
Axioplan 2IE fluorescent microscope. C-control (normal chow), AL-125 mg/kg/day
aqueous extract; AH-500 mg/kg/day aqueous extract; H-50 mg/kg/day
homocysteine; HAL-50 mg/kg/day homocysteine + 125 mg/kg/day aqueous extract;
HAH-50 mg/kg/day homocysteine + 500 mg/kg/day aqueous extract. (*:p<0.05;
**: p<0.001 compared to control)
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2.4 DISCUSSION
2.4.1 Cell Culture Experiments
For ginseng extract to be effective in the attenuation of atherosclerosis, it
needs to ideally be safe for consumption, while also effectively acting to limit
inflammation, oxidation, serum cholesterol levels or some combination of the three.
In atherosclerosis, macrophages are responsible for increased production of IL-ip,
which leads to increased expression of adhesion molecules, specifically VCAM-1 and
ICAM-1 on the surface of endothelial cells, responsible for the recruitment and
adhesion of monocytes to the activated endothelium. This study focused on the
effects of North American ginseng extract in limiting the up-regulated expression of
VCAM-1 and ICAM-1 in aortic endothelial cells in response to inflammatory
stimulation with the common pro-inflammatory cytokine IL-1(3. 25 ’26
The confocal images in this experiment suggest that North American ginseng
extract may have an anti-inflammatory effect by limiting expression of VCAM-1,
\
ICAM-1, or both. With 24-hour pretreatment, both extracts seemed to reduce
expression of VCAM-1 at all concentrations used (Figure 2.4) and only the ethanol
extract noticeably reduced ICAM-1 expression (Figure 2.3).

In the 5-day

pretreatment, only the highest dose of either extract - 500 pg/mL - appeared to be
effective in reducing ICAM-1 (Figure 2.5) and VCAM-1 (Figure 2.6) expression.
However, this may be a result of the cells and the conditions they are kept in
throughout the experiment. The 5-day pretreatment required the cells be grown in
low serum media to prevent excessive proliferation during the experiment, and the
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induction of ICAM-1 and VCAM-1 by IL-ip may have been less robust following 5
days of growth in low serum conditions.
The results seen in this study were consistent with some previous findings,
which suggest ginseng may have some ability to limit adhesion molecule expression..
Wan et al. (2009) showed that Panax notoginseng was able to significantly decrease
TNF-a induced expression of VCAM-1 and ICAM-1 in human coronary artery
endothelial cells in a dose-dependent manner, both qualitatively using an
immunostaining assay as well as quantitatively using an ELISA and quantitative
PCR.8 Other studies however, have found that hyperlipidemic rats treated with Panax
notoginseng showed no change in ICAM-1 expression compared to other groups.
These conflicting results may be due to differences in technique, an artifact of the
limited bioavailability of ginseng when administered orally, or even a difference
between the effects on different species, with the extract being effective on human
cells, but not in rats.
A reduction in expression of either VCAM-1, ICAM-1 or bbth could lead to
protection against atherosclerosis by minimizing monocyte adhesion to the arterial
endothelium and therefore limiting subsequent inflammatory processes and further
lesion formation.28 Although the confocal pictures provide a visual representation of
the effects of ginseng on IL-ip induced VCAM-1 and ICAM-1 expression, a
quantifiable result would be much more convincing. To quantify mRNA levels of
VCAM-1 and ICAM-1, quantitative real-time PCR was attempted, but was
unsuccessful.
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Compared to some previous studies, the conflicting results in this experiment
may be because porcine cells do not react in the same way that human cells do in
culture, or it may be the composition of the ginseng extract. Both Assinewe et d.
(2002) and Zhou & Kitts (2002) found that North American ginseng extract was
capable of increasing TNF-a release from alveolar macrophages or peripheral blood
mononuclear cells29 respectively.

Increased production and release of TNF-a

suggests that Panax quinquefolius (N.A. ginseng) may actually have an immunostimulatory effect,30'32 however, such an effect may also be beneficial in
atherosclerosis, as previous studies have shown that stimulation of monocytes or
macrophages can lead to increased invasion of intimal lesions, lipid uptake and
migration back across the endothelium to clear the lipid.

-j -3

Although not examined here, future studies should strive to include additional
controls such as looking at cells not known to express VCAM-1 and ICAM-1 to
ensure we are not seeing non-specific staining. Additionally, cells should be stained
for an established endothelial marker, such as CD-31 to ensure cells' being examined
are actually endothelial cells. Further studies should aim to confirm the effects of
North American ginseng on the endothelium by successfully quantifying VCAM-1
and ICAM-1 expression with real-time PCR and western blotting.

Quantitative

assessment in this manner would also yield important information about appropriate
ginseng dosages for future in vitro experiments. Another potential future experiment
would be involving digestion of the ginseng extract to account for the bioavailability
of ginseng when ingested orally as is commonly the case.
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2.4.2 Rat Experiments
Following the in vitro work in aortic endothelial cells; the logical next step
was to move to an in vivo model, where the effects of North American ginseng
extract could be assessed in rats.

These experiments added the complexity of

bioavailability following oral administration, as well as concurrently looking at the
efficacy of ginseng in attenuating the initiation of atherosclerosis in response to
common risk factors, including hypercholesterolemia and hyperhomocysteinemia.
The rat studies were also a logical next step in the project looking at resulting changes
in monocyte adhesion following any potential alterations of VCAM-1 or ICAM-1
expression, as well as now allowing an assessment of the short-term effects of
ginseng on serum cholesterol levels.
In the hypercholesterolemic rat model, the ethanol ginseng extract showed a
dose-dependent trend with regards to monocyte adhesion. Although not significant
(p=0.0963), the finding was still interesting. Perhaps if the study were redone with a
dose higher than 250 mg/kg/day or a larger sample size, a significant result would
have been found. There were conflicting results between this study and several done
previously with regards to serum cholesterol levels. One previous study found that
while Panax ginseng was able to significantly reduce triglyceride levels and nonesterified fatty acid levels in a hypercholesterolemic rat model, it was unable to
change serum total cholesterol levels.34 Another group however, found that treatment
with Panax notoginseng was able to significantly lower serum total cholesterol levels,
with varying results on LDL and HDL specific effects in ApoE deficient mice.

o
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It would be ideal to repeat this study using a longer treatment period, which
would allow for further lesion formation as well as a longer time period for the rats to
adapt to and show any potential signs of ginseng treatment.

Also, it would be

beneficial to include a control group, fed normal chow for the duration of the
experiment and an experimental group testing the effects of the aqueous extract in the
rats. Another interesting addition to the study would be to look at the effects of
Panax quinquefolius treatment along with an established treatment such as a statin, as
was done previously by a group studying the effects of Panax notoginseng. 27
To the best of our knowledge we are the first to quantify monocyte adhesion
in a ginseng-treated rat model of hyperhomocysteinemia. The only other research
done focused on the effects of ginseng on hyperhomocysteinemia-induced cardiac
hypertrophy and thickness of the left ventricle.35 Our study yielded an interesting
finding, that the aqueous extract of North American ginseng was capable of
eliminating the significant difference in monocyte adhesion between the control and
the cholesterol group. Previous studies had shown promising effects with respect to
ginseng treating conditions resulting from high homocysteine levels; Zhou et al.
(2005) looked at the effects of specific ginsenosides on porcine coronary arteries ex
vivo and found encouraging results suggesting that certain ginsenosides were capable
of attenuating endothelial dysfunction, superoxide anion production and eNOS downregulation caused by high homocysteine. These previous findings, together with the
findings of this study provide a strong basis for further research on the ability of
ginseng treatment to limit the negative effects of high homocysteine levels, a major
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risk factor for atherosclerosis, leading to oxidative stress and endothelial
aggravation.36

\
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CHAPTER 3

THE EFFECTS OF NORTH AMERICAN GINSENG ON
ATHEROSCLEROTIC PLAQUE FORMATION AND STABILITY IN A
RABBIT MODEL OF ATHEROSCLEROSIS

3.1 Introduction
Previous studies have shown the various ways that ginseng may be potentially
beneficial in the treatment of atherosclerosis. Ginseng has been shown to have anti
inflammatory effects causing a decrease in expression of adhesion molecules and
production of inflammatory cytokines in a number of different species both in vitro
and in vivo.1'3 Ginseng has also been shown to have anti-oxidant properties,
enhancing endothelial-dependent relaxation impaired by hypercholesterolemia,4’5
potentially by increasing nitric oxide (NO) availability,6 or by clearing reactive
oxygen species (ROS) on its own,7 or by increasing expression of RQ£ degrading
Q

enzymes superoxide dismutase (SOD) and catalase. Additionally, previous studies
^

O Q

have shown potential lipid-lowering effects of ginseng by various mechanisms. ’ ’
These three potential actions of ginseng make it a very appropriate candidate for
further studies regarding its ability to attenuate the initiation and progression of
atherosclerosis. North American ginseng specifically has been shown to have several
health benefits,10'12 however a critical evaluation of its efficacy in the treatment of
atherosclerosis has not been done until now.
Although there are current treatments for atherosclerosis, they have various
side effects that could make their long-term use undesirable; for example statins,
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which have been shown to cause muscle pain known as “statin-induced myopathy” as
well as anti-hypertensive drugs such as ACE inhibitors and ARBs, whose use has
been associated with dizziness, low blood pressure, coughing and angioedema to
varying degrees.13-17 North American Ginseng is a natural product, and has been
shown to be safe for consumption even in large doses,10 and therefore, if effective,
would provide an ideal alternative or addition to current treatments for atherosclerosis.
While results are conflicting, several studies indicate that various preparations
of ginseng may be capable of reducing cholesterol levels,8’12,18-21 however this study
was the first to measure the effects of North American ginseng on serum total
cholesterol in a rabbit model. Additionally, lesion area was measured as a fraction of
total aorta area. This is consistent with the approach of several previous studies,
which have taken a similar approach, and have found promising results regarding the
ability of ginseng treatment to limit plaque formation. Wan et al. (2009) studied the
effects of Panax notoginseng on apoE-deficient mice fed a high cholesterol diet, and
found that treatment with 4 mg or 12 mg per day - equivalent to around 250 or 750
mg/kg - was able to significantly reduce plaque size, measured as a percentage of
total area.2 Hwang et al (2008) studied the effects of an aqueous extract of Korean
red ginseng on rabbits fed a high cholesterol diet, and found that daily treatment with
200 mg/kg was able to significantly reduce lesion area, again measured as a
percentage of total aortic area.19 Finally, since it is well accepted that an increase in
smooth muscle cells and decrease in macrophage and lipids is indicative of increased
plaque stability, 22-24 aortas were sectioned and stained for both smooth muscle and

77

macrophages, and a ratio of the two was measured to determine the effects of North
American ginseng on plaque composition and therefore stability.
The long-term rabbit component of this study will provide a well-controlled study to
critically assess the efficacy of North American ginseng in the prevention and
treatment of atherosclerosis. This portion of the study focused on the ability of
ginseng to attenuate the progression of atherosclerosis, specifically, plaque formation
and lipid deposition as opposed to the short-term study focusing on the ability of
ginseng to act as an anti-inflammatory agent, and limit monocyte adhesion to the
endothelium. This study made use of an aqueous and ethanol ginseng extract, as well
as different dosing regimens, and was the first study to examine the effects of North
American ginseng on atherosclerosis in a rabbit model.

3.2 MATERIALS AND METHODS
3.2.1 Experimental D iet and Ginseng Treatment
The rabbits were divided into seven groups (n=10 each) as seen in Figure 3.1.
\
Group 1 was fed normal chow for 7 months and sacrificed; group 2 was fed a 0.25%
cholesterol diet for 7 months and sacrificed; group 3 was fed a 0.25% cholesterol diet
for 4 months and sacrificed; group 4 was fed 0.25% cholesterol for 7 months, but
received 125 mg/kg/day aqueous ginseng extract from 4 months to 7 months; group 5
was fed 0.25% cholesterol for 7 months, but received 250 mg/kg/day aqueous ginseng
extract from 4 month to 7 months; group 6 was fed a 0.25% cholesterol diet for 4
months along with 250 mg/kg/day aqueous ginseng extract; group 7 was fed a 0.25%
cholesterol diet for 4 months along with 250 mg/kg/day ethanol ginseng extract.
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Group 1 rabbits were fed only normal chow served as a negative control for
the experiment, as rabbits did not develop atherosclerosis on this diet. Group 2 acted
as a positive control for groups 4 and 5, as rabbits on a 0.25% cholesterol diet
developed human-like lesions in this time period. Group 3 acted as a positive control
for groups 6 and 7, again because the rabbits developed human-like lesions in this
time period. These rabbits served as a comparison for groups 4 and 5 with respect to
ginseng treatment halting or regressing lesion formation.
Groups 6 and 7 were used to determine the preventative effects of ginseng
when given concurrently with a high cholesterol diet, as well as to determine if one
extract was more effective than the other when given at a dose of 250 mg/kg/day.
Groups 4 and 5 were fed a high cholesterol diet for 4 months to allow lesion
formation, after which, they began treatment with either low or high dose - 125 or
250 mg/kg/day respectively - aqueous ginseng treatment. The aqueous extract was
chosen for these studies, as it appeared to have a greater effect in the preventative
administration studies, as well as being more effective in the homocysteine rat studies
(Chapter 2). For all ginseng treated groups, the ginseng extract was dissolved in
molasses and given daily by oral gavage.
The ginseng extracts used were those characterized by Azike et al. (2011) and
used by Chakrabarti et d. (2011) and Feng et d. (201l).25'27

Figure 3.1 Experimental design for long-term rabbit study. Group 1
rabbits served as a negative control, and were fed normal chow for 7 months. Group
2 rabbits were fed a high cholesterol diet (0.25%) for 7 months. Group 3 rabbits were
fed a high cholesterol diet for 4 months. Group 4 and 5 rabbits were fed a high
cholesterol diet for 7 months, but began receiving 125 or 250 mg/kg/day aqueous
ginseng respectively to determine the effects of ginseng following lesion formation.
Groups 6 and 7 were fed a high cholesterol diet while also receiving either 250
mg/kg/day aqueous or ethanol ginseng extract to determine the preventative effects of
ginseng administration, and if one extract was more effective than the other.
\
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3.2.2 Serum Cholesterol Levels
At two months, four months, and seven months, blood samples were collected
to assess the effects of ginseng on serum total cholesterol levels. Blood was collected
from either the central ear artery - while rabbits were alive - or via intracardiac
puncture - if collected following sacrifice. The blood was then transferred to 15 mL
tubes containing 200 pL of 0.3% EDTA, inverted and placed on ice. Blood was
centrifuged at 5000RPM for 10 minutes at room temperature to separate plasma from
cellular components. Plasma was collected with a transfer pipette, placed into 2 mL
cryotubes tubes, and frozen at -20°C until analyzed.
To analyze serum total cholesterol levels, plasma samples were thawed, and
the Serum E Cholesterol Kit (Wako Diagnostics, Richmond, VA) colorimetric assay
was used. Absorbance at 600 nm was measured using an Omega series micro-plate
reader (BMG Labtech, Ortenberg, Germany) and correlating plasma cholesterol
levels (in mg/dL) were determined using a standard curve.
3.2.3 Lipid D eposition and Lesion Area Quantification

N

To examine lesion area, aortas were removed and separated into thoracic and
abdominal segments. Both segments were first rinsed in 100% propylene glycol
twice, for a total of 15 minutes. They were then stained with 1% oil red o (Sigma
Aldrich Canada, Oakville, ON) in 100% propylene glycol for 30 minutes and then
differentiated in 80% propylene glycol twice for a total of 10 minutes. Aortas were
then pinned out on a black wax dissection tray, and photos were taken using a Canon
Powershot SD880 Is digital elph camera (Tokyo, Japan).
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To quantify lesion area, photos were analyzed using Adobe Photoshop CS4
(San Jose, California). Measurements were taken of both lesion area and total aorta
area and a ratio was used for further data analysis.
3.2.4 Lesion Morphology and Composition
To determine if ginseng treatment had any effect on lesion composition and
morphology, sections of thoracic aorta between the 1st and 2nd intercostal ostia were
cryoprotected in increasing concentrations of sucrose and embedded in Tissue-Tek
Optimal Cutting Temperature (OCT) embedding media (Sakura, Torrance, CA),
frozen in liquid nitrogen-cooled isopentane, kept at -20°C and sectioned using a
cryostat courtesy of Robart’s Research Institute (London, ON). Histological and
immunohistochemical analyses were carried out using 10 pm sections cut just distal
to the first intercostal ostia.
3.2.4.1 Lesion A ssociated Lipid
To examine the presence of lipid, samples were stained with 0.1% Oil Red O
(Sigma Aldrich Canada, Oakville, ON) in 100% propylene glycol, differentiated in
85% propylene glycol and rinsed in distilled water. Samples were then mounted
using VectaMount™ aqueous mounting media (Vector Laboratories Canada,
Burlington, ON), and were analyzed using light microscopy on a Zeiss Axioplan 2IE
(Carl Zeiss Canada, Toronto, ON) equipped with Axiovision LE 4.3 imaging software.
3.2 .4 .2 Calcium D eposition
To analyze calcification and matrix mineralization in atherosclerotic plaques,
samples were stained with Alizarin Red S (Alfa Aesar, Ward Hill, MA). Samples
were then mounted using Cytoseal XYL synthetic mounting media (Thermo
Scientific, Asheville, NC) and analyzed using light microscopy on a Zeiss Axioplan
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2IE (Carl Zeiss Canada, Toronto, ON) equipped with Axiovision LE 4.3 imaging
software.
3.2.4.3 Smooth M uscle Cells
To examine vascular smooth muscle cells, samples were stained with
monoclonal anti-a-smooth muscle actin IgG2a (Sigma Aldrich Canada, Oakville,
ON). Sections were subjected to single-label immunohistochemistry using an
alkaline phosphatase substrate kit (Vector Laboratories) and secondary antibody
horse anti-mouse IgG (H + L) Alkaline Phosphatase conjugate according to the
manufacturer’s instructions. The reaction product was blue, and sections were not
counter-stained. Negative controls omitted primary antibody. Samples were then
analyzed using light microscopy on a Zeiss Axioplan 2IE (Carl Zeiss Canada,
Toronto, ON) equipped with Axiovision LE 4.3 imaging software.
3.2.4.4 Macrophages
To examine macrophages associated with atherosclerotic lesions, samples
were stained with mouse anti-rabbit activated macrophage clone RAMI 1 IgGl (Dako
Cytomation Canada, Burlington, ON). Sections were subjected to single-label
immunohistochemistry using an Alkaline Phosphatase Substrate Kit (Vector
Laboratories) and secondary antibody horse anti-mouse IgG (H + L) Alkaline
Phosphatase conjugate according to the manufacturer’s instructions. The reaction
product was blue, and sections were not counter-stained. Negative controls omitted
primary antibody. Samples were then analyzed using light microscopy on a Zeiss
Axioplan 2IE (Carl Zeiss Canada, Toronto, ON) equipped with Axiovision LE 4.3
imaging software.
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3 .2.4.5 Osteopontin
To examine vascular calficication, samples were stained with mouse anti-rat
osteopontin (MPIIIIBlO(l)) IgGl (Developmental Studies Hybridoma Bank, Iowa
City, IA). Sections were subjected to single-label immunohistochemistry using an
Alkaline Phosphatase Substrate Kit (Vector Laboratories) and secondary antibody
horse anti-mouse IgG (H + L) Alkaline Phosphatase conjugate according to the
manufacturer’s instructions. The reaction product was blue, and sections were not
counter-stained. Negative controls omitted primary antibody. Samples were then
analyzed using light microscopy on a Zeiss Axioplan 2IE (Carl Zeiss Canada,
Toronto, ON) equipped with Axiovision LE 4.3 imaging software.
3.2 .4 .6 Quantifying Lesion Stability
To quantitatively assess the effects of ginseng on lesion composition and
morphology Adobe Photoshop CS4 (San Jose, California) was used. Slides were
stained for a-smooth muscle actin or macrophages and a measurement of total lesion
area was taken with a selection tool. From the total lesion area, a colour range was
selected to determine the composition of the lesion, by measuring the amount of
smooth muscle cells or macrophages as a fraction of total lesion area. To determine
quantitatively whether ginseng treatment influenced plaque composition, a ratio of
smooth muscle cells to macrophages was determined.
3.2.5 Statistical Analysis
Data was expressed as median ± interquartile range and was statistically
analyzed using a Kruskal-Wallis Test for nonparametric data, and a Dunn’s Multiple
Comparison Post Test to compare all pairs of groups. All analyses were done using
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GraphPad Prism (V5, GraphPad Software, Inc., La Jolla, CA). p-values less than 0.05
were considered significant.

3.3 RESULTS
3.3.1 The effect of North American ginseng on serum total cholesterol
levels in a rabbit model o f atherosclerosis
After 2 months of their respective treatments, serum total cholesterol levels of
the cholesterol fed rabbits (groups 2-5) were significantly higher than those of chow
fed rabbits (group 1). However, serum total concentrations did not differ between
cholesterol fed rabbits and groups 6 and 7 treated with 250 mg/kg/day aqueous or
ethanol ginseng extract respectively (Figure 3.2A).
After 4 months, cholesterol fed rabbits (groups 2 and 3) continued to have
significantly higher serum total cholesterol levels than chow fed rabbits. Neither
aqueous (group 6) nor ethanol (group 7) ginseng extract significantly changed serum
total cholesterol levels from the cholesterol fed group (Figure 3.2A).
When rabbits which had been fed a high cholesterol diet for, 4 months were
treated for an additional 3 months with 125 mg/kg/day (group 3) or 250 mg/kg/day
aqueous ginseng extract (group 4) while maintained on a cholesterol diet, neither
ginseng treatment was capable of significantly reducing serum total cholesterols
compared to the cholesterol fed group (Figure 3.2B).

Figure 3.2A N either aqueous nor ethanol North American ginseng
extract has an effect on serum total cholesterol levels in rabbits when
administered concurrently with a high cholesterol diet for 4 months.
Serum cholesterol levels (median ± interquartile range) were measured from 0 to 4
months in rabbits fed normal chow, a high cholesterol diet or a high cholesterol diet
supplemented with 250 mg/kg/day aqueous or ethanol North American Ginseng
extract. Neither ginseng extract was able to significantly change serum total
cholesterol levels compared to cholesterol fed rabbits when given along with a high
cholesterol diet (n=10 for groups 1, 6 and 7, n=40 for groups 2-5)
\
Figure 3.2B Aqueous North American ginseng extract has no effect on
serum total cholesterol levels in rabbits when administered follow ing 4
months o f cholesterol feeding. Serum cholesterol levels (median ± interquartile
range) from 0 to 7 months in rabbits fed normal chow, a high cholesterol diet, and
from 4 to 7 months in rabbits fed a high cholesterol diet supplemented with 125 or
250 mg/kg/day aqueous North American Ginseng extract. Neither dose of aqueous
extract was able to significantly change serum total cholesterol levels compared to the
cholesterol fed group when given following 4 months of cholesterol feeding (n=10).

S e ru m Total Ch olesterol (m^AdL)

Serum Total Cholesterol (mgAdL)
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- • - G ro u p 4: 125 AQ
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3.3.2 The effect of North American ginseng on atherosclerotic lesion
formation (measured by area) in a rabbit model of atherosclerosis
Following 4 months on their respective diets, lesion area was not significantly
different between cholesterol fed rabbits (Figure 3.3B) and rabbits receiving 250
mg/kg/day aqueous (p=0.0576) or ethanol (p=0.1035) North American ginseng
extract, it appeared that the aqueous extract (Figure 3.3C) may have had a greater
impact on lesion formation than the ethanol extract (Figure 3.3D).

However,

regardless of whether lesion area was measured as total (Figure 3.4A) or separated
into abdominal and thoracic lesion area (Figure 3.5A) the result was not significant.
After 7 months, the chow-fed group showed no lesion formation. Rabbits on
a high cholesterol diet for 7 months and those supplemented with either 125
mg/kg/day or 250 mg/kg/day of aqueous North American ginseng extract did not
have significantly different lesion areas when measured either as total (Figure 3.4B),
or separated into thoracic and abdominal lesion area (Figure 3.5B). Although not
significantly different, there was a trend suggesting ginseng treatment actually
increased lesion area.

Figure 3.3 Naïve rabbits treated with either 250 mg/kg/day aqueous or
ethanol ginseng extract did not have significantly different lesion area
than cholesterol-fed rabbits. To analyze the formation of atherosclerotic
plaques, aortas were removed from rabbits following sacrifice, split into thoracic and
abdominal sections, and stained with oil red o. Measurements were taken using
Adobe Photoshop CS4 (San Jose, CA) of thoracic and abdominal area, total aorta area,
thoracic and abdominal lesion area and total lesion area. The data were combined,
and ratios were taken of thoracic lesion area to thoracic aorta area, abdominal lesion
area to abdominal aorta area and total lesion area to total aorta area (TH= thoracic,
AB= abdominal). Shown are samples of lesion selections from (A) thoracic and
abdominal aortas from a group 1 rabbit; (B) thoracic and abdominal aortas from a
group 2 rabbit; (C) thoracic and abdominal aortas from a group 4 rabbit; (D)
thoracic and abdominal aortas from a group 5 rabbit.

A orta

Lesion

Aorta

Lesion

Figure 3.4A N either aqueous nor ethanol North American ginseng
extract has an effect on total atherosclerotic lesion formation in the
aorta of rabbits when administered concurrently with a high
cholesterol diet for 4 months. Percentage of total aorta area covered by lesion
(median ± interquartile range) after 4 months of feeding a high cholesterol diet, or a
high cholesterol diet supplemented with 250 mg/kg/day aqueous or ethanol North
American Ginseng extract. Images were taken with a Canon Powershot SD880 Is
digital elph camera (Tokyo, Japan). Lesion area was detected with oil red o staining
for intracellular lipid, and area measurements were made using Adobe Photoshop
CS4 (San Jose, California).

Figure 3.4B Aqueous North American ginseng extract has no effect on
total atherosclerotic lesion formation in the aorta of rabbits when
administered follow ing 4 months of cholesterol feeding. Percentage of
total aorta area covered by lesion (median ± interquartile range) at 7 months in rabbits
fed normal chow for 7 months, a high cholesterol diet for 7 months, or a high
cholesterol diet for 7 months supplemented for the last 3 months with 125 or 250
mg/kg/day aqueous North American Ginseng extract. Images were taken with a
Canon Powershot SD880 Is digital elph camera (Tokyo, Japan). Lesion area was
detected with oil Red o staining for intracellular lipid, and area measurements were
made using Adobe Photoshop CS4 (San Jose, California).

92

(A)

% Lesion Area

75-1

Cholesterol

250 AQ

250 EtOH

% Lesion Area

(B)

Chow-fed

CH(7)

125 AQ

250 AQ

Figure 3.5A N either aqueous nor ethanol North American ginseng
extract has an effect on atherosclerotic lesion formation in the thoracic
or abdominal aorta of rabbits when administered concurrently with a
high cholesterol diet. Ratio of lesion area to aorta area (median ± interquartile
range) at 4 months in rabbits fed a high cholesterol diet, or a high cholesterol diet
supplemented with 250 mg/kg/day aqueous or 250 mg/kg/day ethanol North
American Ginseng extract. Images taken with a Canon Powershot SD880 Is digital
elph camera (Tokyo, Japan). Lesion area was detected with oil red o staining for
intracellular lipid, and area measurements were made using Adobe Photoshop CS4
(San Jose, California).

Figure 3.5B Aqueous North American ginseng extract has no effect on
atherosclerotic lesion formation in the thoracic or abdominal aorta of
rabbits when administered follow ing 4 months of cholesterol feeding.
Ratio of lesion area to aorta area (median ± interquartile range) at 7 months in rabbits
fed normal chow for 7 months, a high cholesterol diet for 7 months, or a high
cholesterol diet for 7 months supplemented for the last 3 months with 125 or 250
mg/kg/day aqueous North American Ginseng extract. Images taken with a Canon
Powershot SD880 Is digital elph camera (Tokyo, Japan). Lesion area was detected
with oil red o staining for intracellular lipid, and area measurements were made using
Adobe Photoshop CS4 (San Jose, California).
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3.3.3 Lesion Stability - Qualitative Plaque Morphology
Control rabbits did not develop any atherosclerotic lesions as seen in the
‘Control’ column in both figures 3.6 and 3.7. All other groups, whether cholesterolfed or cholesterol-fed and receiving ginseng treatment of any kind showed noticeable
formation of atherosclerotic lesions in the aortic lumen (Figures 3.6 and 3.7 excluding
panels A, E, I, M or Q).
With respect to oil red o staining, naïve animals fed a high cholesterol diet
while also receiving either 250 mg/kg/day aqueous (Figure 3.6C) or ethanol (Figure
3.6D) ginseng extract showed no obvious difference with respect to either lesion size,
presence or localization of lipid compared to animals fed a high cholesterol diet for 4
months (Figure 3.6B).

Similarly, rabbits treated with 125 (Figure 3.7C) or 250

mg/kg/day aqueous ginseng extract (Figure 3.7D) did not yield any obvious
differences from rabbits fed a high cholesterol diet for 7 months (Figure 3.7B). Lipid
in all cholesterol-fed rabbits regardless of ginseng treatment was localized all
throughout atherosclerotic lesions.

'

With respect to the presence of smooth muscle cells, naïve animals fed a high
cholesterol diet while also receiving either 250 mg/kg/day aqueous (Figure 3.6G) or
ethanol (Figure 3.6H) ginseng extract showed no obvious difference with respect to
either lesion size or smooth muscle cell presence or localization compared to animals
fed a high cholesterol diet for 4 months (Figure 3.6F). Similarly, rabbits treated with
125 (Figure 3.7G) or 250 mg/kg/day aqueous ginseng extract (Figure 3.7H) did not
yield any obvious differences from rabbits fed a high cholesterol diet for 7 months
(Figure 3.7F). Smooth muscle cells were found in the media of all aortas, regardless
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of cholesterol feeding. In all cholesterol-fed rabbits, regardless of ginseng treatment
smooth muscle cells were found throughout atherosclerotic lesions, particularly in the
cap region of the lesion.
With respect to the presence of macrophages, naïve animals fed a high
cholesterol diet while also receiving either 250 mg/kg/day aqueous (Figure 3.6K) or
ethanol (Figure 3.6L) ginseng extract showed no obvious difference with respect to
either lesion size or macrophage presence and localization compared to animals fed a
high cholesterol diet for 4 months (Figure 3.6J). Similarly, rabbits treated with 125
(Figure 3.7K) or 250 mg/kg/day aqueous ginseng extract (Figure 3.7L) did not yield
any obvious differences from rabbits fed a high cholesterol diet for 7 months (Figure
3.7J). In all cholesterol-fed rabbits, regardless of ginseng treatment macrophages
were found all throughout atherosclerotic lesions.
With respect to the presence of osteopontin, naïve animals fed a high
cholesterol diet while also receiving either 250 mg/kg/day aqueous (Figure 3.60) or
ethanol (Figure 3.6P) ginseng extract showed no obvious difference With respect to
lesion size, presence, or localization of osteopontin compared to animals fed a high
cholesterol diet for 4 months (Figure 3.6N).

Similarly, rabbits treated with 125

(Figure 3.70) or 250 mg/kg/day aqueous ginseng extract (Figure 3.7P) did not yield
any obvious differences from rabbits fed a high cholesterol diet for 7 months (Figure
3.7N). In all cholesterol-fed rabbits, regardless of ginseng treatment, osteopontin was
found throughout atherosclerotic lesions, some samples had more osteopontin in the
cap region of lesions, but the result was not consistent between all animals.
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With respect to alizarin red s staining, no animals in the study showed aortic
calcification regardless of cholesterol feeding or ginseng treatment (Figures 3.6Q-T
and Figure 3.7Q-T).

\

Figure 3.6 Ginseng treatment in naïve rabbits fed a high cholesterol
diet had no effect on the presence or localization of lipid, smooth
muscle cells, macrophages, osteopontin or aortic calcifcation. Rabbits
(n=10 per group) were fed a diet consisting of only normal chow, normal chow plus
0.25% cholesterol for 4 months, or the high cholesterol diet, in addition to daily oral
gavage of 250 mg/kg aqueous (250 AQ) or ethanol (250 EtOH) North American
ginseng extract. Cryostat sections (10 pm) were taken just distal to the 1st intercostal
ostia and were stained to detect the presence and localization of lipid, smooth muscle
cells, macrophages, osteopontin and calcification. All cholesterol-fed groups
\

developed noticeable atherosclerotic lesions, while chow fed rabbits did not develop
any lesions. The presence and localization of lipid, smooth muscle cells,
macrophages and osteopontin was not affected by treatment with either aqueous or
ethanol ginseng extract when administered concurrently with a high cholesterol diet
in naïve rabbits compared to rabbits fed a high cholesterol diet exclusively. No
calcification was seen regardless of diet or ginseng treatment (Scale bar = 1 mm).
Arrows indicate atherosclerotic lesion formation in the aortic.
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Figure 3.7 Daily treatment with either 125 or 250 mg/kg/day aqueous
ginseng had no effect on the presence or localization of lipid, smooth
muscle cells, macrophages, osteopontin, or aortic calcification when
given follow ing lesion formation from 4 months of cholesterol feeding.
Rabbits (n=10 per group) were fed a diet consisting of either normal chow, normal
chow plus 0.25% cholesterol for 7 months, or the high cholesterol diet for the
duration of the experiment, while also receiving daily oral gavage of either 125 mg/kg
or 250 mg/kg aqueous North American ginseng extract for the final 3 months All
cholesterol-fed groups developed noticeable atherosclerotic lesions, while chow fed
rabbits did not develop any lesions. Cryostat sections (10 pm) were taken just distal
to the 1st intercostal ostia and were stained to detect the presence and localization of
lipid, smooth muscle cells, macrophages, osteopontin and calcification. All
cholesterol-fed groups developed noticeable atherosclerotic lesions, while chow fed
rabbits did not develop any lesions. The presence and localization of lipid, smooth
muscle cells, macrophages and osteopontin was not affected by treatment with either
aqueous or ethanol ginseng extract when administered following 4 months of
cholesterol feeding compared to rabbits fed a high cholesterol diet exclusively. No
calcification was seen regardless of diet or ginseng treatment (Scale bar = 1 mm).
Arrows indicate atherosclerotic lesion formation in the aortic.
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3.3.4 Lesion Stability - Quantification of Plaque Composition
In naïve animals fed a high cholesterol diet while also treated with 250
mg/kg/day aqueous or ethanol ginseng extract (groups 6 and 7), neither extract was
capable of significantly altering the ratio of smooth muscle cells to macrophages
compared to the cholesterol-fed group. The variability was too great to yield a
significant result, but there was a trend suggesting a potential increase in ratio of
smooth muscle cells to macrophages (Figure 3.8A). Similarly, treatment with either
125 mg/kg/day or 250 mg/kg/day aqueous ginseng extract (groups 4 and 5) following
lesion formation did not significantly alter the ratio of smooth muscle cells to
macrophages compared to the cholesterol-fed group (Figure 3.8B).

\

Figure 3.8A Ginseng treatment in naïve rabbits also fed a high
cholesterol diet had no significant effect on the ratio of smooth muscle
cells to macrophages in atherosclerotic lesions. Shown is the ratio (median
± interquartile range) of smooth muscle cells (SMCs) to macrophages in
atherosclerotic lesions of rabbits fed a high cholesterol diet for 4 months, or a high
cholesterol diet supplemented with 250 mg/kg/day aqueous (250 AQ) or ethanol (250
EtOH) North American Ginseng extract for 4 months. Neither ginseng extract was
able to significantly alter the composition of atherosclerotic lesions compared to
cholesterol-fed rabbits.
\

Figure 3.8B Aqueous extract of North American ginseng has no effect
on the ratio of smooth muscle cells to macrophages in rabbits when
administered follow ing atherosclerotic lesion formation. Shown is the
ratio (median ± interquartile range) of smooth muscle cells (SMCs) to macrophages
in atherosclerotic lesions of rabbits fed a high cholesterol diet for 7 months, or a high
cholesterol diet supplemented with 125 mg/kg/day (125 AQ) or 250 mg/kg/day (250
AQ) North American Ginseng extract for 3 months following lesion formation from 4
months of cholesterol feeding. Neither dose of the aqueous ginseng extract was able
to significantly alter the composition of atherosclerotic lesions compared to
cholesterol-fed rabbits.
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3.4 Discussion
This study examined at the effects of different doses of two different extracts
of North American ginseng on the initiation and progression of atherosclerotic lesions
in the hyperocholerterolemic rabbit model. Previous studies have shown that ginseng
treatment may attenuate inflammation, oxidation and serum cholesterol levels.
Therefore it was hypothesized that 1) ginseng could limit the formation of
atherosclerotic lesions when given concurrently with a high cholesterol diet in naïve
animals mimicking a preventative administration paradigm, or 2) halt or alter lesion
progression when given following lesion formation in an interventional
administration paradigm. The major advantages of the rabbit study were that it
allowed for longer term administration of the ginseng extract, and more importantly,
rabbits developed human-like lesions when fed a diet consisting of 0.25% cholesterol
for a long period.

With the development of these more human-like lesions, the

rabbit study provided another opportunity to look at the effects of North American
\
ginseng extract on gross plaque formation in the aorta while also allowing an
assessment of the effects on serum total cholesterol levels over a longer period of
time. To determine the effects of North American ginseng extract on the plaques
themselves, lesion area, morphology and composition were examined, the latter as an
indication of plaque stability.
Prior to this project, there have been few studies examining the effects of
ginseng on atherosclerosis in the rabbit model, but similar to the cell and rat
experiments, there are conflicting results between these studies. Hwang et al. (2008)
found that Korean Red Ginseng decreased serum total cholesterol by 20%, though the
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result was not significantly different from the cholesterol-fed group.19 Ismail et al.
(1999) and Kang et al. (1995) fed rabbits a 2% cholesterol diet for 28 days and 8
weeks respectively, which has been shown to produce foam cell lesions, unrelated to
true atherosclerosis and leading to a lipid storage disease.

in

Also, these studies used

either an unidentified ginseng species,31 Korean Red Ginseng,19 or ginsenosides
isolated from Panax ginseng5 as opposed to aqueous or ethanol extract of North
American ginseng. My study showed that regardless of preventative or interventional
treatment with ginseng, serum total cholesterol levels remained unaffected. This
result was consistent with three previous studies that also found various ginseng
extracts to have no significant effect on serum total cholesterol levels5,14,31 The
issue with comparing these studies to ours is that all have used different methodology
with regards to the induction of hypercholesterolemia as well as the ginseng extract
used in the experiments. Therefore we believe that not only is our methodology more
sound than previous studies, but also that it is a novel finding that North American
ginseng extract - either aqueous or ethanol - is unable to reduce serum'total
cholesterol. However, future studies should look at the effects of North American
ginseng extract on serum triglycerides, or specific effects on lipoprotein profiles,
including LDL or HDL cholesterol.
Next, the effects of North American ginseng extract on lesion formation and
development were studied, focusing specifically on lesion area. A previous study had
shown that an aqueous extract of Korean Red Ginseng was able to significantly
reduce lesion formation in rabbits fed a 0.5% cholesterol diet for 8 weeks, although
lesion formation in this study was measured by the thickness of the intimal
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circumference occupied by the atheroma as opposed to lesion area.19 Our results
appeared to support the findings of this study, since with preventative ginseng
administration the aqueous ginseng extract showed a trend of limiting lesion
formation (p=0.0576). However, the difference in lesion formation was not
statistically significant, and this experiment needs to be repeated with a greater
number of animals to determine if the trend is real. In contrast, in the interventional
administration paradigm, there was a trend, which suggested that treatment with
aqueous ginseng extract could actually increase lesion area in the aorta. These results
suggest ginseng treatment may only be effective in the early stages of atherosclerosis
and hypercholesterolemia, as was seen by Joo et al. (1980), who found that any lipid
lowering effects or potential to inhibit lesion formation were lost when rabbits
received a high cholesterol diet for more than 4 weeks.32
In addition to preventing lesion formation and promoting lesion regression,
many interventional therapies have shown that they can lead to remodeling of lesions
such that they are more stable. Therefore we examined the effect of North American
ginseng on lesion composition as it would relate to lesion stability. To do this, we
looked at the presence of lipid, macrophages, smooth muscle cells, and osteopontin, a
regulator of vascular calcification, important due to the loss of elasticity and potential
stenosis of vessels caused by vascular calcification.33
Qualitatively, there were no obvious differences between rabbits fed a high
cholesterol diet and those receiving ginseng treatment either along with or following
lesion formation. In all rabbits fed a high cholesterol diet, there was lesion formation,
and typical of normal atherosclerotic lesions, lipid and macrophages were found all
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throughout the lesions. Also, consistent with normal plaque morphology, smooth
muscle cells were found throughout the lesion in all cholesterol fed animals,
particularly at the cap region of the lesion, consistent with the formation of a fibrous
cap by extracellular matrix proteins secreted by activated smooth muscle cells.24
Finally, osteopontin presence and localization was not affected by ginseng treatment,
and it was found throughout the lesions, particularly near the cap region in some
animals. This finding is consistent with the finding that foam cells formed by smooth
muscle cells are responsible for producing osteopontin, an important step in the
calcification of atherosclerotic lesions.34
The presence of smooth muscle cells and macrophages in the lesions was
examined and a higher smooth muscle cell to macrophage ratio was taken to indicate
increased lesion stability and therefore a ‘safer’ lesion18,19 Similar to the results
from the lesion area study, the preventative treatment with ginseng extract showed
ginseng given to naïve animals placed on a high cholesterol diet appeared to show
increased levels of smooth muscle cells in comparison to macrophage^, however, this
difference was not statistically significant. In contrast, there was no effect or trend
observed with interventional ginseng treatment. Again, this is consistent with the
previous finding, that ginseng treatment may only be effective in the initial stages of
hypercholesterolemia and atherosclerosis.
Although ginseng was unable to significantly change any of the parameters
examined, this study is the first to show that North American ginseng is ineffective in
treating established atherosclerosis. Despite not being significant, the trends seen
with respect to preventative administration of the aqueous ginseng extract on lesion
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area, and preventative administration of either extract on lesion stabilization are
encouraging, but reinforce the great emphasis that must be placed on timing of
ginseng administration if it is to be effective at all. Interventional therapy, and
preventative treatment with ethanol ginseng extract as stated above, had no effect, and
while preventative administration of the aqueous extract appeared to show a
protective trend, experiments should be repeated with a larger number of animals to
reach a stronger conclusion. Future experiments should likely also include other
controls if possible, including rabbits fed normal chow and ginseng treatment, and a
group receiving an established treatment for atherosclerosis, such as a statin, as has
been done previously.13,19 Another experimental group that could be examined
would be rabbits treated with a combination of ginseng and an established therapy, as
ginseng is safe, and may potentially be a beneficial addition to existing therapeutic
regiments. Furthermore, experiments looking at the expression of various
inflammatory and oxidative markers would strengthen the results of such a study, and
provide important mechanistic data regarding ginseng’s method of action, and
potentially identifying new targets for ginseng therapy.
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CHAPTER 4

SUMMARY

4.1 OVERVIEW OF WORK

Cardiovascular disease is the leading cause of death worldwide, becoming
more prevalent in developing countries with increases in smoking and consumption
of a high-fat “Western” diet.1'3 Current treatments that exist for patients or those at
risk of atherosclerosis, include statins, which act by inhibiting HMG-CoA
Reductase,4'6 the rate-limiting enzyme in cholesterol synthesis, as well as anti
hypertension drugs such as Angiotensin Converting Enzyme (ACE) inhibitors and
Angiotensin Receptor Blockers (ARBs).7 Although shown to be effective, these
pharmaceuticals have also been known to cause several side effects, potentially
\
making their long-term use undesirable, with statins being associated with musclepain known as “statin-induced myopathy” and less commonly hemorrhagic stroke,

Q

and ACE inhibitors and ARBs being associated with dizziness, low blood pressure,
kidney defects, and angioedema.9,10 In contrast, ginseng is a natural health
supplement used for thousands of years for its healing and “adaptogenic” properties,
capable of increasing the body’s defenses against stress, fatigue, and anxiety in a non
specific, non-toxic and normalizing manner.11 Ginseng has been shown to have
various properties that could prove beneficial in the prevention or treatment of
atherosclerosis and therefore we set out to specifically determine if North American
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ginseng, Panax quinquefolius, was capable of attenuating the initiation and
progression of atherosclerosis.
Previous research suggests that ginseng may be capable of attenuating
inflammation,12'17 oxidation,13’18'27 and hyperlipidemia;16,28'33 three main aspects of
atherosclerosis. However, much of this research has been done on other species of
ginseng, and in a number of different animal and cell culture models. Specifically,
we wanted to see if North American ginseng was capable of reducing expression of
adhesion molecules, Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intercellular
Adhesion Molecule-1 (ICAM-1) and accompanying monocyte adhesion to the
endothelium. We also wanted to assess whether North American ginseng had the
same lipid-lowering capabilities as seen in previous studies, and finally if it was
effective in limiting the formation of or stabilizing already-formed atherosclerotic
lesions in both a preventative and interventional treatment paradigm.
In initial experiments, we set out to determine if aqueous or ethanol extract of
North American ginseng was capable of reducing expression of VCA^l-1 and ICAM1 in response to treatment with pro-inflammatory cytokine Interleukin-ip (IL-ip) in
porcine aortic endothelial cells. There was no conclusive result, but confocal images
suggested that 24-hour pretreatment was overall more effective than 5-day
pretreatment, and that the ethanol extract seemed more capable of reducing ICAM-1
expression (Figure 2.4), while both extracts reduced expression of VCAM-1. With 5day pretreatment, only the highest concentration - 500ug/mL, produced a clear
reduction in expression of ICAM-1 (Figure 2.5) and VCAM-1 (Figure 2.6). After
finding this result, an in vivo rat model was used to determine if ginseng was capable
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of attenuating monocyte adhesion to the activated endothelium in either
hypercholesterolemic or hyperhomocysteinemic rats. In hypercholesterolemic rats,
ethanol ginseng extract did not cause any change in serum total cholesterol levels
following 17-days of a high cholesterol diet (Figure 2.8B) and did not produce a
significant change in monocyte adhesion, although there was a trend suggesting that a
higher dose or prolonged ginseng treatment may lead to reduction in monocyte
adhesion (Figure 2.8A). In the hyperhomocysteinemic model, the homocysteine
treated group had significantly higher levels of monocyte adhesion than control rats.
The aqueous extract appeared to be more effective, as treatment with aqueous extract
was able to reduce monocyte adhesion to control-like levels (Figure 2.9B), while
monocyte adhesion in the ethanol extract treated groups remained significantly higher
than controls (Figure 2.9A).
Long-term rabbit studies were carried out to determine if North American
ginseng extract was capable of preventing lesion formation when administered
concurrently with an atherogenic diet, or if it was capable of inhibiting lesion
progression when given to animals with established atherosclerosis. There was no
effect on serum total cholesterol with either preventative (Figure 3.2A) or
interventional (Figure 3.2B) treatment. With respect to lesion formation, we
measured lesion area and found that in the preventative administration paradigm, the
aqueous extract when given at 250 mg/kg/day seemed to reduce lesion area (Figure
3.4A), but the result was not significant. Based on previous rat studies as well as the
findings from the preventative administration portion of the rabbit studies, two
different doses of the aqueous extract were used in the interventional paradigm.
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When administered following lesion formation, there was no significant effect on
lesion area, and in fact, a trend of increasing lesion area was seen with increasing
doses (Figure 3.4B). Morphologically, there were no clear differences between any
of the cholesterol-fed groups, regardless of ginseng treatment. Using
immunohistochemistry, we looked at the prevalence of smooth muscles and
macrophages in the lesions, and took a ratio of the two as a measure of lesion stability.
In the preventative administration group, there was no significant difference between
cholesterol-fed and ginseng treated groups, although there was a trend suggesting
ginseng treatment may increase the smooth muscle to macrophage ratio, indicating
the possibility of lesion stabilization (Figure 3.8A). In the interventional treatment
paradigm, there was no significant difference or trend between the cholesterol-fed and
ginseng-treated groups (Figure 3.8B).
Although we believe that we have done a thorough and critical assessment of
the effects of North American ginseng on atherosclerosis both in vitro and in vivo,
our study was not without limitations. Future studies should look to add to both the
in vitro and in vivo studies by providing a quantifiable result, with respect to adhesion
molecules studied here as well as other markers of inflammation and oxidation
associated with atherosclerosis. Similarly, the hypercholesterolemic rat model could
be improved with the addition of a normal chow fed group, as well as groups treated
with the aqueous extract as well. Finally, with respect to all of the animal studies,
time may have been a major limitation of the study, as the potential effects of North
American ginseng may require treatment for a period longer than our animals were
exposed to.
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4.2 DISCUSSION
The ideal treatment for atherosclerosis would be one that can effectively
attenuate inflammation, oxidation, high cholesterol levels or some combination of the
three, while also being safe for consumption. North American Ginseng is a natural
product, and has been shown to be safe for consumption even in large doses,34 and
therefore, if effective, would provide an ideal alternative or addition to current
treatments for atherosclerosis.
Based on our study, it would appear that North American ginseng alone is not
an ideal candidate for the treatment of atherosclerosis. Although there were some
encouraging results, the lack of significant findings do not provide enough evidence
to dub North American ginseng a cure or effective preventative treatment for
atherosclerosis. That being said, some of the encouraging results do deserve further
consideration. In our preventative treatment model in rabbits, the aqueous extract
caused a noticeable, albeit not significant change in lesion area, and in assessing
\

lesion stability, both extracts caused what seemed like a substantial - although again
not significant - increase in the ratio of smooth muscle cells to macrophages,
indicative of a more stable lesion. These results are consistent with previous studies
that suggest that ginseng may only be effective in acting on the initial stages of
atherosclerosis, though future experiments with more animals are required to further
examine the efficacy of North American ginseng.35
Additionally, there are many other factors of atherosclerosis that North
American ginseng may be capable of acting on. Both Assinewe et al. (2002) and
Zhou & Kitts (2002) found that North American ginseng extract was capable of
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increasing TNF-a release from alveolar macrophages or peripheral blood
mononuclear cells. Increased production and release of TNF-a suggests that Panax
quinquefolius may actually have an immuno-stimulatory effect. '

Such an effect

may be beneficial in atherosclerosis, as previous studies have shown that stimulation
of monocytes or macrophages can lead to increased extravasation into intimal lesions,
lipid uptake and migration back across the endothelium to clear the lipid.40 Also,
previous research suggests North American ginseng is capable of preventing and
limiting obesity, fatty liver and hypertriglyceridemia,41 and of modifying the diabetic
phenotype of Zucker Fatty Diabetic rats42 all risk factors associated with
atherosclerosis.43 Therefore future studies should look to more critically determine
the effects of North American ginseng on these risk factors, specifically as they
pertain to atherosclerosis before it is ruled out as a potential treatment or addition to
existing therapies.
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(AUP) entitled "Imaging Of Atherosclerosis, Aortic Valve Sclerosis And Alzheimer's Disease Using
Rabbit Models
" has been APPROVED by the Animal Use Subcommittee of the University Council on Animal Care.
This approval, although valid for four years, and is subject to annual Protocol Renewal.2007-02301:: 5
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number. x
3. Purchases of animals other than through this system must be cleared through the ACVS
office. Health certificates will be required.
The holder of this Animal Use Protocol Is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional safety
standards and have received all necessary approvals. Please consult directly with your institutional
safety officers.
Submitted by: Copeman, Laura
on behalf of the Animal Use Subcommittee
University Council on Animal Care

